Pancreatic islet xenotransplantation has been advocated as a way of overcoming the shortage of human donor tissue for the treatment of type 1 diabetes. However, the potent immune response against xenografts is a major barrier to their use. We show that a short course of the anti-CD45RB antibody, MB23G2, prolongs survival of fetal pig pancreas grafts in mice. To investigate this effect further we used an i.p. xenograft model in which both donor pig cells and host in¯ammatory cells can be expediently recovered and analyzed. Graft prolongation was associated with reduced T cell and macrophage in®ltration, and reduced production of both T h 1 and T h 2 cytokines at the graft site. Graft survival was further increased and T cell in®ltration further reduced by combining anti-CD45RB antibody with co-stimulation blockade. The primary effect of anti-CD45RB antibody may be on CD4 T cells, in keeping with the marked reduction in T cell cytokine production in both spleen and graft sites. This concurs with previous studies in allogeneic models that indicate that this antibody perturbs T cell responses by modifying signaling via the TCR. In addition, anti-CD45RB treatment led to reduced expression of LFA-1 and CD62 ligand (CD62L) on CD4 T cells, independent of antigenic challenge. LFA-1 may enhance co-stimulation, and both LFA-1 and CD62L are involved in T cell traf®cking. Their reduced expression provides an explanation why the T cell pool is reduced in lymph nodes. We conclude that modulation of in¯ammation against xenografts by anti-CD45RB antibody is due to effects on both T cell priming and traf®cking.
Introduction
Pancreas transplantation offers a cure for type 1 diabetes. Successful transplantation restores normoglycemia, eliminating the need for daily insulin injections, and reducing diabetes side effects such as nephropathy and neuropathy (1, 2) . Due to a shortage of human donor pancreas, there is considerable interest in alternative sources of pancreatic tissue including xenogeneic fetal pig pancreas (FPP). Hyperacute and acute vascular rejection pose a formidable barrier to xenotransplantation of organs that utilize blood vessels of donor origin (3) . However, xenografts, such as those of FPP, which are neovascularized by the graft recipient are not subject to such rejection, but are rejected by T cell-dependent cellular mechanisms (3, 4) .
CD45 is a protein tyrosine phosphatase expressed on all nucleated hematopoietic cells, which plays an important role in regulating immune responses. By dephosphorylating Src-family kinases, CD45 promotes antigen-speci®c B and T cell responses (5) . Negative regulation of CD45 is facilitated by its homodimerization, and in the absence of this interaction mice are subject to lymphoproliferative and spontaneous autoimmune disease (6) . CD45 plays an additional role in regulating selectin expression (7, 8) and integrin function (9, 10) . Recently, CD45 has also been shown to negatively regulate cytokine receptor mediated signaling via JAK-family kinases, thus revealing a role for CD45 in multiple hemopoietic lineages (11) . Multiple isoforms of CD45 are generated by alternative splicing of exons 4, 5 and 6 (also known as A, B and C) which encode part of the extracellular region of the molecule. However, their functional relevance is unclear. T cell activation results in a shift from high to low mol. wt isoforms, which can be detected by decreased intensity of staining with anti-CD45RB antibodies. The CD45RB low phenotype has variously been associated with primed/memory T cells, increased secretion of T h 2 cytokines and a population of T cells with regulatory function (12±15).
Several lines of investigation indicate that anti-CD45 antibody can prevent allogeneic graft rejection. Such antibodies are a major component of polyclonal anti-lymphocyte/antithymocyte globulin preparations (16) which are used clinically to reduce the incidence and severity of early rejection. Monoclonal anti-CD45 antibody has also shown promise in pre-clinical trials (17) . In mice, a short course of the mAb, MB23G2, speci®c for the CD45RB isoform expressed on B and T cells, induces long-term donor speci®c tolerance in a proportion of recipients of allogeneic grafts (18±20). While the mechanism of allograft prolongation induced by anti-CD45RB antibody treatment has not been clearly de®ned, it is apparent that perturbations of T cell responses are involved. Increased tyrosine phosphorylation of phospholipase Cg1, increased production of T h 2 cytokines, decreased expression of CD45RB and increased expression of the CTLA-4-regulatory molecule on CD4 T cells have been reported following treatment with the anti-CD45RB antibody, MB23G2 (18±21).
It is generally believed that xenograft rejection is more potent than allograft rejection. Nevertheless, a common feature of the cellular responses to both allo-and xenografts is dependence on T cells, in particular CD4 T cells (4, 22, 23) . Thus, we were interested in testing the potential of MB23G2 anti-CD45RB antibody to inhibit the cellular xenoresponse to avascular pig tissue. The ef®cacy of MB23G2 was tested in two models: FPP transplantation under the kidney capsule and transplantation of a pig kidney cell line PK15 into the peritoneum. The former model is commonly used as a surrogate for FPP transplantation into humans. The latter model facilitates recovery by peritoneal lavage of both graft and graft-in®ltrating cells, enabling simple quantitation and functional analysis (24) .
Methods

Animals
Mice were bred and maintained at the Walter and Eliza Hall Institute for Medical Research and used at 6±10 weeks of age. Wild-type mice were either BALB/c or B6.C-H-2 bm1 (termed bm1, C57BL/6 with the bm1 mutation of H-2K b ). The production of CTLA-4±Ig mice on a bm1 background has been previously described (25, 26) . CD154 knockout (KO) mice (27) were backcrossed to bm1 and further crossed to CTLA-4±Ig mice to obtain CTLA-4±Ig/CD154KO mice. Outbred Landrace pigs were bred at the Victorian Institute of Animal Science (Werribee, Australia).
Cell lines and antibodies
PK15 and the MB23G2 B cell hybridoma (anti-CD45RB, rat IgG2a) were obtained from ATCC (Rockville, MD). The B cell hybridoma GL117 (anti-b-galactosidase, rat IgG2a) was obtained from Dr J. Abrams (DNAX, Palo Alto, CA). MB23G2 and GL117 mAb were grown, Protein G puri®ed and dialyzed against PBS by the Monoclonal Antibody Facility of this Institute. The following mAb were used for¯ow cytometry: CT-CD4 (anti-CD4; Caltag, Burlingame, CA), 53.6.7 (anti-CD8; Sigma, St Louis, MO), 2D7 (anti-CD11a; PharMingen, San Diego, CA), MEL-14 [anti-CD62 ligand (CD62L); PharMingen], F4/80 (anti-macrophage/monocyte; ATCC), M1/42 (antimouse class I; ATCC) and 2.4G2 (anti-mouse Fcg receptor; ATCC).
FPP transplants under the kidney capsule
Pancreata were harvested from fetal pigs at 85±100 days of gestation and dissected into~2-mm 3 pieces. The segments of pancreas were cultured on Millipore ®lters (Bedford, MA) on a Gelfoam (Upjohn, Kalamazoo, MI) support in DMEM supplemented with 10% FCS. Cultures were maintained in 10% CO 2 / 90% O 2 for 3 days, then 10% CO 2 /90% air for a further 2 days. Four segments of FPP were transplanted under the left kidney capsule (two pieces at the upper pole and two pieces at the lower pole) of BALB/c mice. Mice were treated i.v. with 0.1 mg of Protein G-puri®ed MB23G2 antibody or rat IgG at days ±3 and 0 relative to transplantation (grafts recovered at day 4 or 7 post-transplant) or days ±1, 0 and +5 relative to transplantation (grafts recovered at day 14 or 21 post-transplant). For graft analysis, graft-bearing kidneys were recovered and paraf®n sections were stained with H & E for morphological analysis or for insulin to monitor graft survival. Grafts were scored blindly: 0 = ®brous scar with no insulin-staining graft tissue, 1 = scattered residual insulin-staining cells, 2 = insulinstaining cell clusters with evidence of graft damage, 3 = welldifferentiated insulin-staining clusters with perigraft in®ltrate but no evidence of damage, and 4 = well-differentiated insulinstaining clusters with no in®ltrate. In¯ammation was scored blindly: 0 = no in¯ammatory in®ltrate present, 1 = a few perigraft in¯ammatory cells, 2 = numerous perigraft cells, 3 = intragraft in®ltration, and 4 = dense peri-and intragraft in®ltration.
PK15 transplants into the peritoneum
The indicated numbers of PK15 cells were injected i.p. into the indicated strain of mouse. Mice were treated i.v. with 0.1 mg of Protein G-puri®ed MB23G2 or GL117 isotype control antibody on days ±3 and 0 relative to PK15 transplants. At 5 days posttransplant mice were killed by CO 2 inhalation, and lavages were performed by injecting 5.5 ml of PBS containing 5% FCS and 5 U/ml heparin into the peritoneum. After massaging the abdomen, the lavage¯uid and cells were recovered with a needle and syringe. The recovered volume was noted and generally was~5 ml. Reported cell recoveries were adjusted to re¯ect the total in 5.5 ml.
Flow cytometry
Single-cell suspensions of spleen or lavage cells on ice in PBS containing 1% BSA and 0.05% sodium azide were blocked with 2.4G2 anti-Fcg receptor antibody, and then stained. The mAb used for staining were directly conjugated to¯uoro-chromes or biotinylated and detected using streptavidin± phycoerythrin (Caltag). Cells were analyzed on a FACScan (Becton Dickinson, Mountain View, CA) with CellQuest software.
Cytospins
Peritoneal cells were spun through an FCS cushion in a cytospin onto glass slides and stained with DIFF-Quik (Lab Aids, Narrabeen, NSW, Australia). Between 500 and 800 cells/ slide were scored morphologically.
Assessment of cytokine production ex vivo Splenic CD4 T cells positively selected by MACS (~90% CD4 + by¯ow cytometry) or unfractionated peritoneal cells were cultured at 3 Q 10 6 /well in 1.5 ml of RPMI supplemented with 10% FCS in 24-well plates at 37°C/5% CO 2 without antigen. Supernatants were recovered on day 3 and assayed for the presence of IL-4, IL-5, IL-10 or IFN-g by ELISA. Recombinant cytokines used as standards, coating antibody and biotinylated antibody for detection were obtained from PharMingen, and used according to the manufacturer's instructions.
Results
Anti-CD45RB delays in¯ammation and prolongs xenograft survival
Anti-CD45RB-treated BALB/c mice were grafted with FPP, and graft survival and in¯ammation assessed histologically. Two features were observed: in®ltration of the graft was delayed and graft survival was prolonged by anti-CD45RB treatment (Table 1) . Grafts were well de®ned with minimal in®ltration in both groups at day 4 post-transplant. However, in mice treated with control antibody, all grafts (six of six) were completely destroyed by 7 days post-transplant, at which time a dense in®ltrate was observed at the graft site (Table 1 and Fig. 1A ). The in®ltrate consisted of lymphocytes, macrophages and eosinophils. By contrast, graft tissue was identi®ed in four of four anti-CD45RB-treated mice at day 7 post-transplant (Table 1 and Fig. 1B ). Delayed rejection was also indicated by reduced in®ltration of grafts from the anti-CD45RB-treated mice (Table 1 and Fig. 1B ). Insulin-positive graft tissue persisted in ®ve of six anti-CD45RB-treated mice at day 14 post-transplant (Table 1) ; organized clusters of cells indicative of developing endocrine structures were present (Fig. 1D) , whereas there was no evidence of endocrine clusters or insulin staining of graft sites in control antibody-treated mice (Fig. 1C) . By day 21, all grafts had been destroyed and a dense in®ltrate persisted at the graft site (Table 1) .
In order to identify if the delayed in®ltration of anti-CD45RB-treated FPP grafts was associated with a predominant cell type, immunohistochemical analysis was performed on frozen sections at day 7 post-transplant. There was no discernible difference in CD4 + or CD8 + cell in®ltration. In®ltration by F4/80 + macrophages/monocytes appeared to be reduced in grafts from mice treated with anti-CD45RB (data not shown).
Quantitative analysis of graft and graft in¯ammation in an i.p. challenge model
To con®rm that anti-CD45RB antibody reduces cell in®ltration, we used an i.p. xenograft model (24) . Assessment of histological sections in the FPP model, although useful, is at best semi-quantitative. The advantage of the i.p. model is that the graft and graft-in®ltrating cells can be recovered by peritoneal lavage, enabling both quantitative and functional analysis. Cells of the pig kidney cell line PK15 were grafted i.p. into BALB/c mice treated with anti-CD45RB or control antibody. Lavages were performed on day 5 post-transplant, corresponding to the peak of T cell in®ltration (24) . The effect of anti-CD45RB treatment mirrored that observed for FPP grafts under the kidney capsule, i.e. graft survival was prolonged and the in¯ammatory response was reduced. Indeed, the number of lavage cells was reduced from 16.7 to 4.4 Q 10 6 (e.g. Fig. 2A, 3 .3 T 0.7-fold reduction, n = 8 experiments). Notably, the number of lavage cells from anti-CD45RB-treated, PK15-grafted mice was no different from that of normal mice ( Fig. 2A) . PK15-graft cells were identi®ed morphologically in cytospins (Fig. 2C ) and by their mouse class I ± , high SSC pro®le in FACScans (Fig. 3A, upper panels) . Anti-CD45RB treatment protected PK15 xenograft cells as shown by the increased number of grafted cells recovered ( Figs 2B and 3C ).
Morphological assessment of cytospins showed that the in¯ammatory response in the i.p. PK15 challenge model also resembled that of FPP grafts, with macrophages, lymphocytes and polymorphs identi®ed at the graft site ( Fig. 2A and C) . Anti-CD45RB treatment led to a dramatic reduction in the number of macrophages/monocytes in the lavage (7.5 T 5.2-fold reduction, n = 3 experiments, e.g. Fig. 2A ). Lymphocyte numbers were also reduced, although less dramatically than for macrophages/monocytes (2.2 T 1.2-fold reduction, n = 3 experiments, e.g. Fig. 2A ). Both eosinophils and neutrophils were present in lavages (Fig. 2C ), but their numbers were not reproducibly reduced by anti-CD45RB treatment.
Flow cytometry of the lavage con®rmed the ®ndings of the cytospin histology (Fig. 3) . Anti-CD45RB treatment reduced in®ltration by CD4 (2.6 T 0.2-fold reduction, n = 4 experiments e.g. Fig. 3A and B) and CD8 (4.9 T 1.6-fold reduction, n = 2 experiments, e.g. Fig. 3A and B) lymphocytes. However, the most dramatic effect of the anti-CD45RB treatment was the marked reduction in macrophages/monocytes (7.8 T 3.9-fold reduction, n = 3 experiments, e.g. Fig. 3B ), as determined by F4/80 staining (Fig. 3A) .
Anti-CD45RB reduces cytokine production at the graft site A preferential increase in IL-4 and IL-10 (as determined by RT-PCR) occurs in allografts from anti-CD45RB-treated mice (18, 20) . By contrast, we have not found any evidence of cytokine skewing in xenografted mice treated with anti-CD45RB antibody. Perhaps this is because the xenograft response is already dominated by T h 2 cytokines (28). Peritoneal lavage cells were recovered 5 days after PK15 transplantation and cultured in vitro without adding PK15 cells. Cytokine secretion into culture medium was quanti®ed by ELISA. Secretion of IL-4, IL-5, IL-10 and IFN-g was reduced by anti-CD45RB treatment of the mice (Fig. 4) . Given that cytokine secretion by lavage cells obtained from normal mice or anti-CD45RB + PK15-treated mice was frequently below the limit of detection, we are unable to report the relative fold reduction. However, a reduction in production of each of these cytokines was observed in three independent experiments.
Anti-CD45RB reduces CD4 T cell responses, but not numbers in the spleen
The rapid rejection of neovascular xenografts is dependent on CD4 T cells (22, 23) . For instance, we have shown that a proportion of FPP grafts survive beyond 8 weeks in mice rendered permanently and completely CD4 de®cient by the transgenic expression of anti-CD4 antibody (23), compared to rejection within 7 days in wild-type mice (e.g. Fig. 1B) . Thus, we wished to examine the effect of anti-CD45RB treatment on priming of xenoreactive CD4 T cells in the spleen. CD4 T cell recovery from PK15 cell-challenged mice was not reduced by anti-CD45RB treatment (Fig. 5A) . Over ®ve experiments, the ratio of CD4 T cells in the spleen of anti-CD45RB + PK15:control antibody + PK15-treated mice was 1.3 T 0.3. Thus, anti-CD45RB antibody did not simply deplete splenic CD4 T cells.
Assessment of cytokine secretion showed that anti-CD45RB treatment clearly had a negative effect on CD4 T cell priming. Splenic CD4 T cells were enriched to~90% by positive selection on MACS and cultured without restimulation, enabling assessment of ex vivo cytokine production in ELISA. A comparison of CD4 T cells from mice given PK15 grafts plus control antibody treatment with those from normal mice showed that graft-activated T cells secreted IL-4, IL-5, IL-10 and IFN-g (Fig. 5B) . Anti-CD45RB treatment impaired production of each of these cytokines (Fig. 5B) . IL-2 levels after 20 h of culture were <16 pg/ml in all test groups. These trends were observed in two experiments, as well as for ex vivo cultures of unfractionated spleen cells (data not shown).
The effect of anti-CD45RB is enhanced by co-stimulation blockade
The aforementioned experiments indicated that anti-CD45RB treatment prolonged xenograft survival, but did not prevent eventual rejection. Co-stimulation blockade has also received considerable attention as a means of prolonging allograft and xenograft survival. In particular, blockade of the co-stimulatory interaction of CD28 on T cells with CD80/86 on antigenpresenting cells (APC) and that of CD154 on T cells with CD40 on APC has been effective in many model systems (29±31). Hence, we also examined the relative ef®cacy of co-stimulation blockade alone or combined with anti-CD45RB treatment. CD28±CD80/86 blockade was achieved by the use of recipient mice transgenic for CTLA-4±Ig. CD154±CD40 blockade was achieved by the use of CD154KO recipient mice. These experiments demonstrated that the combination of anti-CD45RB with co-stimulation blockade was advantageous. Co-stimulation blockade, as was the case for anti-CD45RB antibody, reduced CD4 T cell in®ltration, but the combination was more effective (Fig. 6A) . Indeed, anti-CD45RB treatment of CTLA-4±Ig/CD154KO mice essentially prevented CD4 T cell in®ltration (Fig. 6A) . Co-stimulation blockade alone was ineffective at enhancing PK15 graft survival, few PK15 cells being recovered from CTLA-4±Ig, CD154KO or CTLA-4±Ig/ CD154KO mice (Fig. 6B) . Anti-CD45RB antibody alone was as effective as co-stimulation blockade (Fig. 6B) . Notably, anti-CD45RB treatment and co-stimulation blockade synergized to enhance PK15 graft survival. The most pronounced effect was observed when anti-CD45RB antibody was combined with blockade of both CD28 and CD154 co-stimulatory pathways (Fig. 6B) . Thus, the number of grafted cells surviving after antibody treatment was 50,000 cells and CD28/CD40 ligand co-stimulation blockade was 25,000 cells, whereas the two together was 1,700,000 cells.
CD62L and LFA-1 expression is reduced after anti-CD45RB antibody treatment
Various T cell activation markers were examined in order to determine if anti-CD45RB treatment blocked the activation of xenoreactive T cells. In the spleen of PK15-grafted mice treated with anti-CD45RB versus control antibody there was no consistent reduction in the numbers of CD4 cells positive for CD25 or CD44 (data not shown). By contrast, CD62L expression was reduced, the CD62L high population observed in control antibody-treated PK15-grafted mice being replaced by a CD62L low population (Fig. 7) . Notably, the reduction in CD62L expression was not restricted to xenoreactive T cells, but rather appeared to be a direct affect of the anti-CD45RB antibody alone. Thus, the shift affected the majority of cells (Fig. 7A ) and a similar reduction was obtained in the absence of PK15 challenge (data not shown). Anti-CD45RB treatment of PK15-grafted mice similarly resulted in a reduced intensity of staining for LFA-1 (detected using antibody speci®c for the anti-CD11a chain of LFA-1, Fig. 7) . Again, this shift was not restricted to xenoreactive CD4 cells, but rather affected the majority of cells (Fig. 7) , and was also observed for CD4 cells from untransplanted mice (data not shown).
Anti-CD45RB reduces CD4 T cell numbers in lymph nodes, but not in spleen CD62LKO and LFA-1KO mice show reduced homing of lymphocytes to lymph nodes, but not the spleen (32, 33) . Hence, we wished to determine if reduced expression of CD62L and LFA-1 after anti-CD45RB treatment similarly affected the homing of CD4 T cells. Ungrafted mice were treated with anti-CD45RB or control antibody and analyzed 3 days later. CD4 T cell recovery from inguinal and iliac lymph nodes was reduced 2-to 3-fold (Fig. 8) , whereas the recovery from the spleen was not reduced (Fig. 8) . This result was con®rmed in two additional experiments in which anti-CD45RB treatment selectively reduced CD4 T cells in the inguinal nodes (but not spleen) by 2-to 3-fold (data not shown). CD8 T cell recovery in the inguinal nodes was similarly reduced (data not shown).
Discussion
Antibodies against different CD45 isoforms or different epitopes of the same isoform can elicit different biological effects and only some have been shown to prolong allograft survival (16±20,34). One such antibody, MB23G2, has been shown to promote establishment of allografts (renal and islets) and result in a state of donor-speci®c tolerance in a proportion of recipients (18, 19) . However, this antibody alone had little effect on the survival of vascular xenografts (cardiac and renal) (35) . Humoral and cellular responses both contribute to rejection of such xenografts that utilize blood vessels of donor origin, and it was proposed that the failure of MB23G2 alone to prolong graft survival was due to a failure to prevent production of xenoreactive antibodies (35) . By contrast, we have Fig. 6 . Anti-CD45RB antibody synergizes with co-stimulation blockade to (A) decrease graft in¯ammation by CD4 T cells and (B) enhance PK15 graft survival. The indicated strain of mouse was transplanted i.p. with 2 Q 10 7 PK15 cells and peritoneal lavages were performed 5 days latter for FACS analysis as described in Fig.  3 . Mice were treated as indicated on the x-axis. Co-stimulation blockade alone treated mice were administered isotype control antibody. Graphs show the mean T SD recovery/mouse for n = 3 mice/group. shown for the ®rst time that this anti-CD45RB antibody prolongs survival of neovascularized FPP and avascular PK15 xenografts. The rejection of such xenografts which do not depend on donor vasculature is predominantly mediated by cellular mechanisms, leading to the conclusion that the anti-CD45RB antibody-induced xenograft prolongation is a result of perturbation of these cellular responses.
Differences in vascularity (neovascularized versus avascular) and graft site (kidney versus peritoneum) may result in varied effectors of FPP and PK15 xenograft destruction being evoked. Nevertheless, a number of studies have indicated that the potency of the cellular xenograft response is controlled by T cells, in particular CD4 T cells (22, 23, 36) . Hence, we exploited the versatile and quantitative nature of the PK15 graft model to study the effect of anti-CD45RB antibody on T cells. The action of anti-CD45RB antibody appears to be multifaceted. Firstly, a modest (2-fold) reduction of blood lymphocytes (19) and lymph node CD8 T cells (20) results from anti-CD45RB treatment. We also observed a 2-to 3-fold reduction in CD4 and CD8 T cell numbers in lymph nodes. By contrast, there is no reduction in T cell (both CD4 and CD8) numbers in the spleen. This paradox is not readily reconciled by a depletion mechanism. Instead, the restriction of this reduction in T cell numbers to lymph nodes and blood can be explained by altered traf®cking, especially given the changes in the CD62L and LFA-1 homing/adhesion molecules. Secondly, the reduction in cytokine production by splenic CD4 T cells (without a reduction in numbers) supports the view that anti-CD45RB directly affects T cell priming. Thirdly, anti-CD45RB may affect T cell traf®cking to the in¯ammatory site. The expression of CD62L and LFA-1 is reduced, and the numbers of cells in the graft site is reduced in the i.p. xenograft model. These issues are discussed further below.
Although not expressly shown by our study, the existing literature supports the view that the effects of anti-CD45RB antibody treatment on T cell priming are direct. CD45 has an important role in positive regulation of T cell responses (5) . Previous reports have indicated that some anti-CD45RB antibodies directly affect TCR-mediated signaling. For example, anti-CD45RB antibody increases phosphorylation of phospholipase Cg1 in an anti-CD3 activated T cell hybridoma suggesting direct modi®cation of signaling via the TCR (19) . Furthermore, anti-CD45RB treatment increases CD4 T cell expression of the negative regulator of co-stimulation, CTLA-4 (21). Our ®nding that anti-CD45RB treatment reduces splenic CD4 T cell cytokine production, but not number, or expression of activation markers such as CD25 and CD44, suggests that the frequency of responding CD4 T cells is not reduced in the spleen, but rather that outcome of antigen recognition is qualitatively altered. The production of both T h 1 (IFN-g) and T h 2 cytokines (IL-4, IL-5 and IL-10) was reduced by anti-CD45RB treatment, indicative of a dampened rather than a deviated immune response. This was true for both afferent sites (e.g. unfractionated spleen cells and puri®ed splenic CD4 T cells) and effector sites (e.g. lavage cells in the peritoneal graft site). This contrasts with what has been described for allografts (18, 20) , where the levels of T h 2 cytokines IL-4 and IL-10 was increased while that of IFN-g was unaltered. In addition to reduced T cell cytokine production and in®ltration, there was a dramatic reduction in macrophage numbers at the graft site of anti-CD45RB-treated mice. This is of interest as macrophages are abundant in rejecting FPP and PK15 xenografts, and activated macrophages can directly destroy xenografts (24) . T cells produce proin¯ammatory cytokines (37, 38) that promote macrophage in®ltration and/or expansion (38±40) at the graft site. Thus, the reduction in macrophage numbers may be attributed to reduced T cell in®ltration and function. Nevertheless, we have found that CD45RB is expressed on a subset of macrophages (data not shown) such that it is possible that anti-CD45RB antibody treatment may also directly affect macrophage in®ltration or expansion.
Anti-CD45RB antibody targeting of signaling via the TCR has recently been shown to synergize with co-stimulation blockade (with anti-CD154 antibody) to promote allograft survival (20) . To determine whether this synergism also applied to the xenograft response, we investigated the effect of anti-CD45RB treatment combined with blockade of CD28 and CD154. The combination of anti-CD45RB antibody with blockade of either CD154 or CD28 costimulation was advantageous in both reducing CD4 T cell in®ltration of the graft and promoting xenograft survival. The effect was even more marked when anti-CD45RB antibody was combined with blockade of both CD28 and CD154. Not only was there an additional enhancement of xenograft survival, but CD4 T cell in®ltration was essentially ablated. We suggest that the synergy of these agents re¯ects not only compatibility of targeting both TCR signaling and co-stimulation, but also the advantage of blocking multiple co-stimulatory interactions. Many studies including our own have demonstrated the advantage of combined co-stimulation blockade, including combined blockade of CD28 and CD154, and CD28 and LFA-1 [e.g. (29, 41, 42) ]. Reduced LFA-1 expression in anti-CD45RB-treated mice might also have contributed to the reduction in co-stimulation, given the importance of LFA-1 in interactions between T cells and APC (38, 43, 44) . Of relevance to our ®ndings above, one study showed that activation of transgenic CD4 T cells without ICAM-1/LFA-1 Fig. 8 . Anti-CD45RB treatment reduced CD4 cell numbers in the lymph nodes, but not spleen of ungrafted mice. Mice were treated with either isotype control (hatched bars) or anti-CD45RB (®lled bars) antibody as indicated on the x-axis. Three days later, spleen and lymph nodes were recovered and CD4 cells were quanti®ed by FACS analysis. Graphs show the mean T SD recovery/mouse for three mice/group. interaction resulted in normal proliferation, but impaired production of CCL3 and CCL4 chemokines (38) . Upon adoptive transfer, such T cells had a reduced capacity to recruit macrophages.
Our ®nding of decreased CD4 T cells in peripheral lymph nodes, but not spleen of anti-CD45RB-treated mice is suggestive of altered traf®cking of these cells rather than direct elimination. The anti-CD45RB-induced reduction in expression of CD62L and LFA-1 is consistent with this possibility. CD62L (the ligand for peripheral node addressin) and LFA-1 (an adhesion molecule with many functions including binding to vascular endothelium) promote lymphocyte homing to peripheral lymph nodes such that CD62LKO and LFA-1KO mice show a similar phenotype to anti-CD45RB-treated mice, i.e. a reduction in lymphocyte numbers in peripheral lymph nodes, but not the spleen (32, 33) . A role for CD45 in regulating lymphoid cell traf®c is also supported by the ®nding that restoration of CD45 expression in CD45KO mice promotes lymphocyte accumulation in the lymph nodes, but not spleen (45) . Both LFA-1 and CD62L have also been implicated in directing leukocytes to sites of in¯ammation (32,46±48) . It is probable that the anti-CD45RB antibody exerts its effects on lymphocyte number and expression of CD62L and LFA-1 directly. Thus, we have shown that these effects are produced by anti-CD45RB treatment in the absence of an antigenic challenge. Furthermore, several studies have indicated a role for CD45 in regulating CD62L expression and the function of various integrins including LFA-1. Anti-CD45RB treatment in vitro resulted in down-regulation of surface CD62L (7, 8) .
Comparison of CD45 ± and CD45 + cells has shown that CD45 can regulate adhesive interactions mediated by b 1 and b 2 integrins (9,10). Furthermore, certain anti-CD45 antibodies (but not all) can inhibit LFA-1-dependent homotypic aggregation of lymphocytes (49, 50) , possibly by inhibiting tyrosine phosphorylation of molecules following LFA-1 engagement (50) . Given its effects on lymph node populations and on the homing/adhesion molecules, it is likely that altered traf®cking (as well as the altered T cell activation described above) contributes to the reduced level of in®ltration in the i.p. xenograft model. Impressive progress has been made in the area of immunosuppression for clinical allotransplantation. Indeed, recent improvements in the immunosuppressive protocol for recipients of allogeneic pancreatic islet transplants has enabled the majority of recipients to become insulin independent (51) . Nevertheless, the supply of human donor pancreas is inadequate to meet demand. The use of xenogeneic (e.g. pig) pancreas would overcome the problem of supply, but not of rejection. Thus, the demonstration that anti-CD45RB antibody treatment enhances the survival of avascular pig xenografts is notable, particularly given its multifaceted action and synergism with co-stimulation blockade.
